Summary
3.39 0.19(5.94%)10/04/2024
Editas Medicine Inc (EDIT)
Editas Medicine Inc (EDIT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 5.77 | -2.45 | -3.14 | -25.74 | -50.15 | -51.91 | -84.44 | -81.37 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.39 | |
| Open | 3.30 | |
| High | 3.48 | |
| Low | 3.25 | |
| Volume | 2,876,799 | |
| Change | 0.19 | |
| Change % | 5.77 | |
| Avg Volume (20 Days) | 1,776,355 | |
| Volume/Avg Volume (20 Days) Ratio | 1.62 | |
| 52 Week Range | 3.15 - 11.69 | |
| Price vs 52 Week High | -71.00% | |
| Price vs 52 Week Low | 7.62% | |
| Range | 2.73 | |
| Gap Up/Down | 0.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 288 | |
| EBIDTA | -106,383,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 52.07 | |
| Book Value | 8.6750 | |
| Earnings Per Share | -3.2310 | |
| EPS Estimate Current Quarter | -0.8200 | |
| EPS Estimate Next Quarter | -0.8600 | |
| EPS Estimate Current Year | -3.0600 | |
| EPS Estimate Next Year | -3.3300 | |
| Diluted EPS (TTM) | -3.2310 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.8760 | |
| Return on asset (TTM) | -0.2068 | |
| Return on equity (TTM) | -0.4155 | |
| Revenue TTM | 24,494,000 | |
| Revenue per share TTM | 0.3710 | |
| Quarterly Revenue Growth (YOY) | -0.9010 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -67,264,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3815 | |
| Revenue Enterprise Value | 59.4061 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 68,398,496 | |
| Shares Float | 66,684,099 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.32 | |
| Institutions (%) | 74.50 | |
10/03 18:00 EST - globenewswire.com
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities
10/01 19:53 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today.
Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today.
09/25 11:46 EST - seekingalpha.com
Editas Medicine: A Risk/Reward Worth Considering
Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks.
Editas Medicine: A Risk/Reward Worth Considering
Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks.
09/17 17:26 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O'Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald.
Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O'Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald.
09/06 09:54 EST - 247wallst.com
Buy These 3 Small-Cap Stocks for 90% to 301% Returns
There has been a noticeable shift in the stock market over the last two months.
Buy These 3 Small-Cap Stocks for 90% to 301% Returns
There has been a noticeable shift in the stock market over the last two months.
09/05 23:19 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.
Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.
09/04 19:17 EST - seekingalpha.com
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody.
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody.
08/28 09:00 EST - globenewswire.com
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:
08/08 10:35 EST - zacks.com
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
08/07 09:05 EST - zacks.com
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago.
08/07 07:00 EST - globenewswire.com
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates.
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates.
07/31 07:00 EST - globenewswire.com
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update.
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update.
07/17 11:30 EST - investorplace.com
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
07/09 07:59 EST - investorplace.com
3 Profitable CRISPR Stocks Earning Analysts' Praise
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.
3 Profitable CRISPR Stocks Earning Analysts' Praise
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.
07/08 09:00 EST - investorplace.com
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease.
06/26 21:33 EST - investorplace.com
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
06/25 08:00 EST - investorplace.com
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the applications are vast and transformative.
06/17 09:15 EST - zacks.com
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
06/14 03:01 EST - globenewswire.com
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
06/14 03:00 EST - globenewswire.com
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion